ReviewFrontiers in pharmacology2026
Managing dry eye disease - a review of selected traditional Chinese medicine and some of their metabolites focusing on molecular mechanisms and signaling pathways.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) is a prevalent global health issue that negatively impacts quality of life. It is also associated with the risk of corneal ulceration, scarring, and even blindness in severe cases. The complex, multifactorial pathology of DED, often conceptualized as a vicious cycle involving tear film instability, hyperosmolarity, inflammation, and apoptosis, complicates treatment. Traditional Chinese Medicine (TCM) offers a potential therapeutic approach by targeting multiple components and pathways. This review systematically describes the mechanisms by which TCM-derived metabolites, botanical drug extracts, and TCM formulas are reported to modulate interconnected pathological processes underlying DED to establish a theoretical framework for intervention optimization. A systematic literature search was conducted on 23 April 2025, across seven electronic databases (PubMed, Web of Science, Embase, SinoMed, CNKI, Wanfang, and VIP) using a comprehensive strategy combining MeSH terms and keywords related to DED, TCM, and signaling pathways. DED involves alterations in several important signaling pathways associated with inflammation, oxidative stress, and apoptosis. These include PI3K/AKT, MAPK, NF-κB, NLRP3, Nrf2, SIRT, AMPK, and VEGF. TCM formulas represent a multi-target approach with an ability to simultaneously target single or multiple signaling pathways involved in DED pathology. This is proposed to counteract key interlinked processes of inflammation, apoptosis, and oxidative stress, and promotes tear film stability in cellular and animal models, thereby highlighting its pharmacological potential. The multi-component, multi-target, and multi-pathway approach of TCM may offer a strategic advantage for managing the multifactorial pathology of DED through the potential to simultaneously regulate multiple interactive signaling networks. This review describes the molecular mechanisms underlying these traditional treatment practices and offers a robust foundation for future clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.